pocketful logo light
pocketful logo light
Kobo Biotech Ltd logo

Kobo Biotech Ltd

NSE: BSE: 531541

₹2.97

(4.95%)

Wed, 27 May 2026, 05:19 pm

Kobo Biotech Share Price Live Chart

1 Day

(4.95%)

No Result Found

Summary

  • Market Cap

    8.55

  • Net Profit

    -5.55

  • P/B

    1.14

  • Sector P/E

    45.56

  • P/E

    0

  • EV/EBITDA

    0

  • Debt/Equity (Industry)

    0.24

  • Interest Cover (Industry)

    9.79

  • ROCE (Industry)

    14.04

  • RONW (Industry)

    13.17

  • ROE

    0

  • ROCE

    0

  • Debt/Equity

    3.38

  • EPS (TTM)

    0

  • Dividend Yield

    0

  • Book Value

    -55.79

  • Interest Cover

    -0.43

Analysis

all

thumbs up icon

Pros

  • Avon Lifesciences's cash and other short term assets cover its long term commitments.
  • The tenure for the Avon Lifesciences board of directors is about average.
thumbs up icon

Cons

  • Unable to calculate sustainability of dividends as Avon Lifesciences has not reported any payouts.
  • Unable to evaluate Avon Lifesciences's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Avon Lifesciences's dividend against the top 25% market benchmark as the company has not reported any payouts.
  • Avon Lifesciences's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
  • Debt is not well covered by operating cash flow (8.2%, less than 20% of total debt).

Read More

Financials

No Result Found

Read More

Ratios

No Result Found

Read More

Shareholding

ShareholdersMAR 2026DEC 2025SEPT 2025JUN 2025MAR 2025
Promoters44.9544.9544.9544.9544.95
FII00000
DII0.000.000.000.000.00
Public55.0555.0555.0555.0555.05
Government00000

Read More

Technical Analysis

RSI

-

MACD

-

50 DMA

-

200 DMA

-

Support and Resistance

TypeR3R2R1PPS1S2S3
Classic-------
Fibonacci-------
Camarilla-------

Pivots Level: Classic

R3

+-

-

R2

+-

-

R1

+-

-

-
-
Pivot Point
LTP: -

S1

--

-

S2

--

-

S3

--

-

Moving Average

SMAEMA

Period

Value

  • 10-EMA

    -

  • 20-EMA

    -

  • 30-EMA

    -

  • 50-EMA

    -

  • 100-EMA

    -

  • 200-EMA

    -

Read More

Corporate Actions

Announcement DatePurposeActionEx Date
09 Sept 2023agm
19 Sept 2022agm
08 Nov 2021agm

Read More

Peer Comparison

No Result Found

Kobo Biotech Ltd logo

Kobo Biotech Ltd

Torrent Pharmaceuticals Ltd logo

Torrent Pharmaceuticals Ltd

Dr Reddys Laboratories Ltd logo

Dr Reddys Laboratories Ltd

Sun Pharmaceutical Industries Ltd logo

Sun Pharmaceutical Industries Ltd

Cipla Ltd logo

Cipla Ltd

Divis Laboratories Ltd logo

Divis Laboratories Ltd

Read More

Kobo Biotech Ltd About

Kobo Biotech is primarily engaged in the business of manufacturing Active Pharmaceutical Ingredients (API) based on Fermentation technology.

Industry

Pharmaceuticals - Indian - Bulk Drugs & Formln

Founded

1993

Headquarters

CEO

Ajit Kamath

Employees

Contact

Website icon

Website

http://www.kobobiotech.com

Email icon

Email

info@kobobiotech.com

Phone icon

Phone

Location icon

Location

Ground Flr D No 8-2-684/J/8/A, Bhavani Nagar Banjara Hills, Hyderabad, Telangana, 500034

Read More

Kobo Biotech Ltd Company History

YearHistory
2011
  • The company recommended a dividend of Re. 1/- i.e. 10% per equity share of Rs 10/- each
2013
  • Mr. Rajendra Kaimal was appointed as Non-Executive Director on the Board of Directors
2014
  • Mr. Jignesh Patel was appointed as Company Secretary and Compliance Officer
  • Dr. Sunil Pitroda was appointed as an Additional Director in the category of Non-Executive Independent Director
2015
  • The company changed its name from Avon Organics Ltd to Avon Lifesciences Ltd.
2020
  • The company name was changed to Kobo Biotech Ltd. from Avon Lifesciences Ltd.

Read More

Deals

Client NameDeal TypeOrder SideQTYAvg PriceDate
SIDDHARTH CHIMANLAL SHAH .bulkBuy1750005.7710 Dec 2018
JINESH ASHWIN MATALIAbulkSell1674675.710 Dec 2018
MBM FINANCIAL SERVICESbulkBuy14714914.1231 Oct 2017
BLUE PEACOCK SECURITIES PRIVATE LIMITEDbulkSell33305512.6925 Oct 2017
BHAVIN Y MEHTAbulkBuy7502212.6925 Oct 2017
BHAVIN Y MEHTAbulkSell12931212.6925 Oct 2017
J V SHAHbulkSell20000019.6520 Apr 2016
J V SHAHbulkBuy20000018.4520 Apr 2016
VIRAL DINESH SHAHbulkBuy16629851.7227 Oct 2015
VIRAL DINESH SHAHbulkSell16629850.9327 Oct 2015

Read More

Kobo Biotech Ltd News

Kobo Biotech NCLT Approves Beaufond Resolution Plan

NCLT Hyderabad approves Beaufond Industries' resolution plan for Kobo Biotech on May 11, 2026, with a total resolution amount of INR 70.11 crores and post-merger shareholding restructuring.

13 May 2026

companies

Kobo Biotech Files Q4 FY26 SEBI Compliance Certificate

Kobo Biotech Limited submitted its quarterly compliance certificate under SEBI Regulation 74(5) for Q4 FY26, confirming proper dematerialization processes through its registrar XL Softech Systems Ltd.

15 Apr 2026

companies

Kobo Biotech confirms non-Large Corporate status

Kobo Biotech Limited confirms it does not fall under SEBI's Large Corporate category as of March 31, 2026, in compliance with regulatory framework for debt securities issuance by large entities.

15 Apr 2026

companies

Kobo Biotech's Committee of Creditors Approves Resolution Process Costs and Professional Fees

Kobo Biotech Limited's Committee of Creditors held its sixth meeting and approved several resolutions with high voting margins. The committee approved costs incurred by Resolution Professional Namrata Randeri from the last meeting with 99.12% voting share, authorizing her to operate bank accounts and manage expenses. Professional fees totaling Rs. 95,500 were ratified with 100% approval, including Rs. 15,000 for advocate M.S. Mano Ranjani for re-filing applications against tax departments, Rs. 40,000 for advocate V.S. Sharma Kollapudi for land document procurement, Rs. 80,500 for operational expenses at Solapur factory maintenance, and Rs. 20,000 additional fees for land building valuation updates. The committee also ratified the extension of time until April 15, 2025 for Prospective Resolution Applicants to submit resolution plans with 99.12% approval. All approved costs will be treated as Insolvency Resolution Process costs.

30 Oct 2025

corporate action

Kobo Biotech's Committee of Creditors Approves 90-Day Extension for Insolvency Resolution Process

Kobo Biotech Limited's Committee of Creditors held its fifth meeting and approved several key resolutions with 98.86% voting share. The committee approved a 90-day extension for the Corporate Insolvency Resolution Process from February 13, 2025 to May 14, 2025, requiring an application to be filed with NCLT Hyderabad Bench. Other approvals included ratification of expenses incurred by the Resolution Professional up to January 17, 2025, appointment of advocate M.S. Mano Ranjani with fees of Rs. 35,000-45,000 for filing the extension application, and appointment of a process advisor for evaluation of resolution plans. The committee also approved legal action against Commercial Tax Department Telangana to recover Rs. 1.97 crores from asset auction proceeds and ratified extension of time for Prospective Resolution Applicants to submit resolution plans until February 8, 2025. Namrata Randeri serves as the Resolution Professional authorized to operate bank accounts and execute these resolutions.

30 Oct 2025

corporate governance

Read More